GovChime
Notice ID: 32077ca1ef804bf7a045b7e942833a48Solicitation

Midazolam Autoinjectors Project Bioshield

Archived on August 14, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−04:00
Posted
July 15, 2021
Notice type
Solicitation
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
ASPR BARDA DIV CONTRACTS MGMT & ACQ
Last updated
Sep 9, 2025

Identifiers

Solicitation number
75A50121R00003
Notice ID
32077ca1ef804bf7a045b7e942833a48

Description

This Request for Proposal (RFP) covers the advanced research and development, procurement, and delivery of adult and pediatric midazolam autoinjectors that have received FDA approval for the treatment of status epilepticus seizures (including seizures caused by nerve agents) in adult and pediatric populations (2+ years of age). Please see attached RFP for additional details.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75A50121R00003
  1. Pre-Solicitation
  2. Solicitation

Award typically follows within 30–90 days after the response deadline. (estimate)

  1. Pre-SolicitationOct 22, 2020

    Midazolam Autoinjectors Project Bioshield

    Notice a4442b7877034a10935d1e1b2f517973 on SAM.gov

  2. 3×
    SolicitationCurrentJun 17, 2021

    Midazolam Autoinjectors Project Bioshield

    Notice 32077ca1ef804bf7a045b7e942833a48 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75A50121R00003

Archive Date

Aug 14, 2021

Office Address

Washington, DC, 20515